Canary in the Coalmine: Pfizer R&D
Executive Summary
In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.
You may also be interested in...
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
Pfizer's Change Management: Unfamiliar Faces
The dust at Pfizer still hasn't settled as new CEO Jeff Kindler shakes up the senior office suite at the world's largest pharmaceutical company. But the dust hasn't obscured the basic message: Pfizer's strategic and managerial model hasn't worked. What's more, the Big Pharma's board is one of a handful in the industry coming to similar conclusions.